Consistent with data from the cell lines, JNJ-165 and either TKI synergized to inhibit the proliferation of cells expressing BCR/ABL from newly diagnosed patients with CML-CP and from patients with CML-AP or BP (Figure 5J). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.